Principal Investigator
Eric Nuermberger, MD

I obtained my MD degree from Vanderbilt University School of Medicine and trained in Internal Medicine and Infectious Diseases at The Johns Hopkins Hospital. Since 2001, our laboratory team has been engaged in translational drug development research using animal and in vitro models of tuberculosis. This work has informed the clinical development of moxifloxacin, rifapentine, bedaquiline, pretomanid, clofazimine and oxazolidinones, as well as novel regimens comprising one or more of these drugs, for treatment of active and latent tuberculosis. My positions on the scientific agenda-setting committees of the TB Trials Consortium (TBTC) and the AIDS Clinical Trials Group’s TB Transformative Science Group and co-chairing the Preclinical and Clinical Sciences Working Group of the Critical Path to TB Regimens initiative, have facilitated the efficient translation of pre-clinical results to inform clinical trial designs. More recently, our efforts have expanded to include drug and regimen development for Buruli ulcer, a neglected tropical disease caused by Mycobacterium ulcerans, and chronic lung infections caused by the Mycobacterium avium and Mycobacterium abscessus complexes. Our work has been sponsored by the National Institutes of Health, the Global Alliance for TB Drug Development, the Bill and Melinda Gates Foundation, the U.S. Food and Drug Administration, and a number of pharmaceutical sponsors and other private foundations.